
Rheumatology in Practice

Reference list

Keat A, Seewoodhary J. Infections and arthritis. *Rheumatology in Practice* 2008; **6.3**: 13–16.

1. Cassinotti P, Bas S, Siegl G, Vischer TL. Association between human parvovirus B19 infection and arthritis. *Ann Rheum Dis* 1995; **54**: 498–500.
2. Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. *Ann Rheum Dis* 2002; **61**: 623–625.
3. Maillefert JF, Muller G, Falgarone G et al. Prevalence of hepatitis C virus infection in patients with rheumatoid arthritis. *Ann Rheum Dis* 2002; **61**: 635–637.
4. Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. *Ann Rheum Dis* 2007; **66**: 1384–1387.
5. Kerr JR, Umene K. The molecular epidemiology of parvovirus B19. *Rev Med Microbiol* 1997; **8**: 21–31.
6. Neshor G, Moore TL. Human parvovirus infection. *Infect Med* 1997; **14**: 638–642.
7. Byrne PA, Hosein IK, Camilleri J. Methicillin-resistant *Staphylococcus aureus* septic arthritis: urgent and emergent. *Clin Rheumatol* 1998; **17**: 407–408.
8. http://www.rheumatology.org.uk/guidelines/guidelines_other (last accessed 08 August 2008)
9. Ponce de León D, Acevedo-Vásquez E, Sánchez-Torres A et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. *Ann Rheum Dis* 2005; **64**: 1360–1361.
10. Ratkay LG, Zhang L, Tonzetich J, Waterfield JD. Complete Freund's adjuvant induces an earlier and more severe arthritis in MRL-lpr mice. *J Immunol* 1993; **151**: 5081–5087.
11. Edwards CJ, Cooper C, Fisher D et al. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. *Arthritis Rheum* 2007; **57**: 1151–1157.
12. Schneeweiss S, Setoguchi S, Weinblatt ME et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. *Arthritis Rheum* 2007; **56**: 1754–1764.
13. Dixon WG, Watson K, Lunt M et al. British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. *Arthritis Rheum* 2006; **54**: 2368–2376.
14. Guignard S, Gossec L, Salliot C et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. *Ann Rheum Dis* 2006; **65**: 1631–1634.
15. Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. *Ann Rheum Dis* 2000; **59**(Suppl 1): i21–i27.
16. Salvati EA, Robinson RP, Zeno SM et al. Infection rates after 3175 total hip and total knee replacements performed with and without a horizontal unidirectional filtered air-flow system. *J Bone Joint Surg Am* 1982; **64**: 525–535.

17. Marculescu CE, Berbari EF, Hanssen AD *et al.* Outcome of prosthetic joint infections treated with debridement and retention of components. *Clin Infect Dis* 2006; **42**: 471–478.
18. Ford DK, Tingle AJ. Cell-mediated immune responses in patients with recurrent arthritis following rubella immunization. *J Rheumatol* 1980; **7**: 225–230.
19. Zonneveld-Huijssoon E, Ronaghy A, Van Rossum MA *et al.* Safety and efficacy of meningococcal C vaccination in juvenile idiopathic arthritis. *Arthritis Rheum* 2007; **56**: 639–646.
20. Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. *Ann Rheum Dis* 2002; **61**: 623–625.
21. Mody GM, Parke FA, Reveille JD. Articular manifestations of human immunodeficiency virus infection. *Best Pract Res Clin Rheumatol* 2003; **17**: 265–287.
22. Vasquez JC, Hart M, Denney CF, Pedowitz R, Ziegler EJ. Fungal arthritis of the knee caused by *Candida parapsilosis* in a kidney transplant recipient. *J Clin Rheumatol* 2002; **8**: 147–150.
23. Greenwood BM, Mohammed I, Whittle HC. Immune complexes and the pathogenesis of meningococcal arthritis. *Clin Exp Immunol* 1985; **59**: 513–519.
24. Toivanen A, Yli-Kerttula T, Möttönen T. Antibiotics in the treatment of reactive arthritis. *Current Rheumatology Reviews* 2006; **2**: 303–308.
25. Taylor-Robinson D, Keat A. How can a causal role for small bacteria in chronic inflammatory arthritides be established or refuted? *Ann Rheum Dis* 2001; **60**: 177–184.
26. Shulman ST, Ayoub EM. Poststreptococcal reactive arthritis. *Curr Opin Rheumatol* 2002; **14**: 562–565.
27. Kerr JR, Cartron JP, Curran MD *et al.* A study of the role of parvovirus B19 in rheumatoid arthritis. *Br J Rheumatol* 1995; **34**: 809–813.
28. Ejtehadi HD, Freimanis GL, Ali HA *et al.* The potential role of human endogenous retrovirus K10 in the pathogenesis of rheumatoid arthritis: a preliminary study. *Ann Rheum Dis* 2006; **65**: 612–616.
29. Cox CJ, Gaston JSH, Kempell KE. RT-PCR of bacterial ribosomal RNA for detection and characterisation of bacterial species in arthritis synovial tissue. *Immunology* 1999; **98**(Suppl 1): 118.